Aggregated from the cited literature below. We summarize sources — we don't author claims.
Mazdutide is described in the provided sources as a once-weekly dual agonist targeting glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Research efforts reported include randomized clinical trials in obesity/overweight (including a phase 3 trial in Chinese adults), trials in type 2 diabetes (including phase 2 and phase 3 trials, and placebo- or comparator-controlled designs), and mechanistic/omics work in a mouse model addressing cognitive dysfunction in diabetes/obesity contexts. A systematic review also summarized emerging obesity pharmacotherapies and reported ongoing phase 3 activity for GLP-1/glucagon dual agonists including mazdutide. (PMIDs: 39305981, 39952695, 40421736, 37943529, 41407860, 41407859, 38092790, 41407859, 40479843)
Mechanism (as reported)
Research described mazdutide as a dual agonist of GLP-1R and GCGR (glucagon-like peptide-1 and glucagon receptors). (PMIDs: 40421736, 37943529, 41407860, 41407859, 38092790, 40479843)
Key findings (each cites a source)
A systematic review and network meta-analysis of randomized controlled trials reported that mazdutide was among seven GLP-1 receptor agonists/polyagonists included for weight-loss outcomes in obesity or overweight, with primary outcome defined as percentage change in body weight from baseline. (PMIDs: 39305981) [PMID 39305981]
A phase 3 randomized, double-blind, placebo-controlled trial in Chinese adults with obesity/overweight reported mean percentage body-weight change at week 32 of -10.09% with 4 mg mazdutide and -12.55% with 6 mg mazdutide versus 0.45% with placebo, and reported that the proportion achieving at least 5% weight reduction at week 32 was higher with mazdutide than placebo. (PMIDs: 40421736) [PMID 40421736]
The same phase 3 obesity/overweight trial reported that at week 48, mean percentage body-weight change was -11.00% (4 mg), -14.01% (6 mg), and 0.30% (placebo). (PMIDs: 40421736) [PMID 40421736]
In the phase 2 randomized, double-blind, placebo-controlled trial in Chinese adults with type 2 diabetes, the primary outcome was change in HbA1c at week 20, and reported mean HbA1c reductions with mazdutide (range -1.41% to -1.67%) versus placebo (0.03%). (PMIDs: 37943529) [PMID 37943529]
In the phase 2 trial in Chinese adults with type 2 diabetes, the same report stated that mean percent body-weight change at week 20 was dose dependent and reached up to -7.1% with mazdutide, with dulaglutide and placebo also reported. (PMIDs: 37943529) [PMID 37943529]
In Chinese adults with type 2 diabetes, a randomized phase 3 trial comparing mazdutide with dulaglutide reported that both mazdutide doses showed non-inferiority and superiority to dulaglutide for mean change in HbA1c from baseline to week 28. (PMIDs: 41407860) [PMID 41407860]
In that same phase 3 type 2 diabetes trial, significantly greater reductions in body weight were reported with mazdutide than with dulaglutide at week 28. (PMIDs: 41407860) [PMID 41407860]
In a phase 3 trial in Chinese adults with type 2 diabetes (mazdutide monotherapy vs placebo), the primary endpoint at week 24 was HbA1c, and the report stated that mazdutide significantly reduced HbA1c versus placebo. (PMIDs: 41407859) [PMID 41407859]
In the same placebo-controlled type 2 diabetes phase 3 trial, weight loss at week 24 was reported in the mazdutide groups versus placebo. (PMIDs: 41407859) [PMID 41407859]
A phase 2 randomized controlled trial (interim analysis) in Chinese overweight adults or adults with obesity reported mean percentage body-weight changes at week 24 of -6.7% (3 mg), -10.4% (4.5 mg), -11.3% (6 mg) versus 1.0% with placebo, and stated dose-associated differences versus placebo were statistically significant. (PMIDs: 38092790) [PMID 38092790]
Preclinical research in a male db/db mouse model investigated mazdutide versus dulaglutide using behavioural tests, brain pathology assessments, and multi-omics analysis, reporting improvements in cognitive performance and neurodegenerative markers with mazdutide compared with dulaglutide in that model. (PMIDs: 40479843) [PMID 40479843]
A systematic review of emerging pharmacotherapies for obesity reported that there were ongoing phase 3 trials on GLP-1/glucagon receptor agonists including mazdutide (and also survodutide) among the included pipeline agents. (PMIDs: 39952695) [PMID 39952695]
Vendor test rankings (10)
Vendors ranked by their independent third-party test grade for Mazdutide, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.6% across 31 tests. Not our verdict.
Labs: ILS Laboratories, Janoshik Labs, liquilabs, freedomdiagnosticstesting.com, Vanguard Laboratory, BioRegen, Trust Pointe Analytics, SR Bio Labs.
Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y · Nature communications · 2023 · PMID 38092790
FAQ
What is Mazdutide?
Mazdutide (2259884-03-0, IBI362, GTPL13924) is classified under glp-1 & incretin agonists, currently studied in clinical trials. Research goals associated with it include metabolic & weight.
Is Mazdutide FDA-approved?
Not yet — Mazdutide is investigational and currently in clinical trials.
What does the research on Mazdutide say?
peptideone aggregates 11 references from PubMed for Mazdutide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.